How many UTIs constitute a recurrent UTI?

A recurrent UTI is medically defined as two or more confirmed urinary tract infections within a 6-month period, or three or more infections within a 12-month period.

Why do I keep getting UTIs even after taking antibiotics?

Recurrent UTIs despite antibiotic treatment can occur due to antibiotic resistance, reinfection, incomplete eradication, or underlying anatomical or hormonal factors. A specialist evaluation with urine culture is essential.

Can recurrent UTIs be prevented?

Yes - recurrent UTIs can often be significantly reduced or eliminated with the right prevention strategy including low-dose antibiotic prophylaxis, vaginal estrogen therapy for postmenopausal women, behavioral modifications, and evidence-based supplements.

Do I need to see an infectious disease specialist or can my primary care doctor treat recurrent UTIs?

While primary care physicians can treat individual UTI episodes, recurrent UTIs benefit significantly from infectious disease specialist evaluation with specialized training in antibiotic resistance patterns and evidence-based prevention strategies.

Is long-term antibiotic use for UTI prevention safe?

Low-dose antibiotic prophylaxis for recurrent UTI prevention has a well-established safety record when properly managed. Specialists carefully select the safest antibiotic at the lowest effective dose and regularly reassess.

Does Atlas IDP accept insurance for recurrent UTI treatment?

Yes, Atlas Infectious Disease Practice accepts most major insurance plans. Call (561) 995-6971 to verify your specific insurance coverage before your appointment.

Contagion Live Archives

Frequent Hepatitis C Testing Among PWID Found to Be Cost-Effective, Study Finds

[ad_1] Lin Zhu, PhD Credit: Stanford University This article was originally posted on our sister-site,

July 14, 2025 No Comments

Quickening a Rapid HCV Test Reduces True and False Positives

[ad_1] Shortening the time to read the OraQuick HCV antibody test from the recommended 20

July 13, 2025 No Comments

FDA Approves Moderna’s COVID-19 Vaccine For in Children Aged 6 Months Through 11 Years

[ad_1] The FDA has approved the company’s COVID-19 vaccine, mRNA-1273 (Spikevax), in children 6 months

July 11, 2025 No Comments

Specialty Pharmacy Integration of Oral Fecal Microbiota Spores Enables Medication Access in Over Half of Patients with Recurrent C difficile Infection

[ad_1] C. diff spore Image credits: Unsplash A recent quality improvement initiative at Henry Ford

July 11, 2025 No Comments

Frequent Hepatitis C Testing Among PWID Found to Be Cost-Effective, Study Finds

Quickening a Rapid HCV Test Reduces True and False Positives

Top 5 Infectious Disease News Stories Week of July 5-12

FDA Approves Moderna’s COVID-19 Vaccine For in Children Aged 6 Months Through 11 Years

Specialty Pharmacy Integration of Oral Fecal Microbiota Spores Enables Medication Access in Over Half of Patients with Recurrent C difficile Infection

Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership

FDA Accepts New Drug Application for Merck’s HIV Treatment, Doravirine/Islatravir

Universal Hepatitis C Screening in EDs Detects More Infections, But Gaps in Care Remain

A Young Mother With C difficile Deals With Social Isolation, Concerns of Recurrence

A Win for Coverage, But Can People Still Access HIV Prevention?

Schedule an Appointment

Quick Links

Patient Forms

Contact Us